Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145064 | 1.00 | LMNA (0.50) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| SCHEMBL7151180 | 1.00 | LMNA (0.50) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| SCHEMBL240241 | 1.00 | LMNA (0.50) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| SCHEMBL16897738 | 1.00 | LMNA (0.50) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| SCHEMBL7147703 | 1.00 | LMNA (0.50) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| SCHEMBL1703992 | 1.00 | LMNA (0.50) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| Propylene Glycol SCHEMBL6265783 | 0.89 | TDP1 (0.53) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| SCHEMBL11853416 | 0.83 | USP2 (0.42) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| SCHEMBL29242642 | 0.82 | LMNA (0.53) | LMNAALDH1A1L3MBTL1TDP1THRB | |
| E968 SCHEMBL11668989 | 0.82 | LMNA (0.75) | LMNAALDH1A1L3MBTL1TDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10433544-B2 | Herbicide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-10-08 | — | — | US | claimed |
| US-20180279609-A1 | Herbicide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2018-10-04 | — | — | US | claimed |
| WO-2018182774-A1 | HERBICIDE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-10-04 | — | — | WO | claimed |
| CN-101084235-A | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS INC (US) | 2007-12-05 | — | — | CN | claimed |
| EP-4504883-B1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | PROCTER & GAMBLE (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4504883-A1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | The Procter & Gamble Company (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4463534-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | The Procter & Gamble Company (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023196452-A1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | THE PROCTER & GAMBLE COMPANY (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230323250-A1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-10-12 | — | — | US | disclosed |
| WO-2023137409-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| US-10433544-B2 | Herbicide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-10-08 | — | — | US | disclosed |
| WO-2018182774-A1 | HERBICIDE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-10-04 | — | — | WO | disclosed |
| CN-101084235-B | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS INC | 2012-10-17 | — | — | CN | disclosed |
| EP-1695088-B1 | METHOD FOR ANALYSING METABOLITES | MAX PLANCK GESELLSCHAFT (DE) | 2012-04-18 | — | — | EP | disclosed |
| WO-2009058277-A1 | NOVEL NITRILE AND AMIDOXIME COMPOUNDS AND METHODS OF PREPARATION | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| CN-101084235-A | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS INC (US) | 2007-12-05 | — | — | CN | disclosed |
| US-20070141712-A1 | Method for analysing metabolites | MAX-PLANCK-GESSELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-06-21 | — | — | US | disclosed |
| EP-1695088-A1 | METHOD FOR ANALYSING METABOLITES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005059556-A1 | METHOD FOR ANALYSING METABOLITES | MAX PLANCK GESELLLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | BCAT2, MTR, ASNS | LMNA 793/4885ALDH1A1 3811/4885L3MBTL1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.